secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0001493152-23-008494
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagenic Therapeutics announces 1-for-4 reverse stock split to comply with Nasdaq minimum bid price rule
--------------------------------------------------------------------------------

- Reverse split effective 5:01 p.m. ET March 22, 2023; split-adjusted trading Nasdaq opens March 23, 2023.
- Goal: meet Nasdaq Rule 5550(a)(2) $1.00 minimum closing price for continued listing.
- Outstanding shares reduced from ~17,285,261 to ~4,321,315; no fractional shares—rounded up to next whole.
- Proportionate adjustments to exercise prices and shares underlying outstanding options, warrants, and equity awards.
- Authorized shares and par value unchanged; new CUSIP 74365N202; ticker remains PTIX.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000149315223008494/0001493152-23-008494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000149315223008494/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-008494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer